Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1238 details
Primary information
ID1851
ThPP IDTh1238
Therapeutic Peptide/Protein NameSusoctocog alfa
SequenceAIRRYYLGAVELSWDYRQSELLRELHVDTRFPATAPGALPLGPSVLYKKT view full sequnce in fasta
Functional ClassificationIb
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life~17 h
DescriptionIntravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA).
Indication/DiseaseFor the treatment of Haemophilia A
PharmacodynamicsImmediately after release in the patient’s circulation, Factor VIII binds to von Willebrand factor (vWF). The Factor VIII/von Willebrand factor complex consists of two molecules (Factor VIII and von Willebrand factor) with different physiological functions. Activated Factor VIII acts as a co-factor for activated Factor IX, accelerating the conversion of Factor X to activated Factor X, which ultimately converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed.
Mechanism of ActionBlood coagulation factor replacements, Factor X stimulants
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesBlood coagulation factors, Antihaemorrhagics
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
Targetvon Willebrand factor
Information of corresponding available drug in the market
Brand NameObizur
CompanyNA
Brand DiscriptionOBIZUR (antihaemophilic Factor VIII (recombinant), porcine sequence) is a purified protein that has 1448 amino acids with an approximate molecular mass of 175kDa. It is produced by recombinant DNA (rDNA) technology in baby hamster kidney (BHK) cells. The BHK cells are cultured in media that contains fetal bovine serum. The manufacturing process is free of human serum and human protein products and does not contain any additional animal derived materials.
Prescribed forIt is indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.
Chemical NameNA
FormulationEach powder vial contains nominally 500 Units of B domain deleted antihaemophilic Factor VIII (recombinant), porcine sequence, susoctocog alfa.
Physcial AppearancePowder and solvent for solution for injection.
Route of AdministrationIntravenous
Recommended DosageThe recommended initial dose is 200 U per kilogram bodyweight, given by intravenous injection
Contraindicationlife-threatening hypersensitivity reactionsto OBIZUR or its components, including hamster protein.
Side EffectsHypersensitivity reactions, including anaphylaxis, may occur. Should symptoms occur, discontinue OBIZUR and administer appropriate treatment
Useful Linkhttps://www.baxter.com/assets/downloads/obizur_pI.pdf , http://www.obizur.com/ , http://drugspider.com/drug/susoctocog-alfa
PubMed ID27098420
3-D StructureN.A.